Solvias to Build Biologics and Cell & Gene Therapy Testing Center in Research Triangle Park
KAISERAUGST, Switzerland, May 6, 2024 /PRNewswire/ -- Solvias announced today that it is expanding its global network of laboratory testing centers with a new biotech site in Research Triangle Park, N.C. It is the company's latest investment to expand its analytical testing services supporting life science organizations with the growing number of cell and gene therapies (CGTs) and biologics in use and under development.
- KAISERAUGST, Switzerland, May 6, 2024 /PRNewswire/ -- Solvias announced today that it is expanding its global network of laboratory testing centers with a new biotech site in Research Triangle Park, N.C.
- It is the company's latest investment to expand its analytical testing services supporting life science organizations with the growing number of cell and gene therapies (CGTs) and biologics in use and under development.
- It will offer critical cell-based potency assays, advanced Next-Gen Sequencing (NGS) capabilities, and related testing services supporting multiple biologic modalities.
- From the outset, the new testing center will support characterization and release testing of CGT and other advanced therapies, including Adeno-Associated virus (AAV) gene therapies, mRNA therapies and antibody drug conjugates.